Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04656678
• Other study ID #: 20-0562
• Status: Recruiting
• Phase: N/A
• Start date: November 25, 2020
• Est. completion date: October 30, 2025

Study information

• Verified date: February 2024
• Source: Northwell Health
• Contact: Ardeshir R Rastinehad, DO
• Phone: 212-434-6580
• Email: Arastine[@]northwell.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using ultrasound only during the cryoablation of the prostate. The software application may aid doctors in locating a prior biopsy proven cancer location from the UroNav biopsy that patients previously had and then use that information to guide the treatment.

Description:

This is a single-center, prospective, single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. All subjects will be treated and then followed up clinically for up to 24 months to evaluate any procedure or device related adverse events as well as to assess efficacy endpoints of the study. Additional data related to quality of life of treated subjects will also be collected

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 30, 2025
• Est. primary completion date: October 30, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have documented histological or cytological evidence of tumor(s) of the prostate.

2. Patients must be = 45 years of age.

3. Patients must be able to read, understand and sign an informed consent.

4. Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging.

5. Prostate cancer is diagnosed by MR image guided biopsies.

6. Gleason Score = 7; and 2 or less positive lesions on prior MR US fusion guided prostate biopsy.

7. A non MRI visible cancer detected via systematic standard biopsy will not be considered an exclusion condition provided the non-MRI visible cancer is singularly located in the contralateral hemisphere of the prostate; is Gleason 6 cancer; and comprises no more than 6mm linear extent of cancer in a single core on standard biopsy.

8. If any standard biopsy cores are positive on the same hemisphere of the prostate gland, they must be confirmed as likely to form a contiguous lesion with the target lesion detected on MRI and therefore be from the same location in the prostate as MR lesion was biopsied and proven to be cancerous. (e.g., Left/Right, Base, Mid Gland, Apex).

9. Prior mpMRI results dated within 120 days prior to ablation.

10. No metastatic disease as per NCCN guidelines (www.nccn.org) - Bone scan indicated to r/o metastatic disease if clinical T1 and PSA > 20 or T2 and PSA > 10

11. PSA < 15 ng/ml or PSA density < 0.15 ng/ml2 in patients with a PSA > 15 ng/ml.

Exclusion Criteria:

1. ASA status > 3

2. Very Low Risk Prostate Cancer based on Epstein's Criteria having a tumor <0.2 cc (AUA Guidelines 2017 pg. 9) GG1, PSA < 10 ng/ml, no more than two positive cores and no core > 50% involvement.

3. Contraindications to MRI 3.1 Claustrophobia 3.2 Implanted ferromagnetic materials or foreign objects 3.3 Known intolerance to the MRI or US contrast agents. 3.4 Severely abnormal coagulation (INR>1.5)

4. Patients with unstable cardiac status including:

4.1 Unstable angina pectoris on medication 4.2 Patients with documented myocardial infarction within 40 days prior to enrolment 4.3 Congestive heart failure NYHA class IV 4.4 Patients with unstable arrhythmia status, already on anti-arrhythmic drugs

5. Severe hypertension (diastolic BP > 100 on medication)

6. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

7. History of orchiectomy, PCa-specific chemotherapy, brachytherapy, cryotherapy, Photodynamic therapy or radical prostatectomy for treatment of prostate cancer; any prior radiation therapy to the pelvis for prostate cancer or any other malignancy.

8. Patient under medications that can affect PSA for the last 3 months prior to UroNAV Ablation system aided cryo-ablation treatment (Androgen Deprivation Treatment)

9. Patients with lesions of Gleason 7 or greater outside the planned treatment area.

10. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately 3 hrs.)

11. Any rectal pathology, anomaly or previous treatment, which could change acoustic properties of rectal wall or prevent safe US probe insertion (e.g., fistula, stenosis, fibrosis, inflammatory bowel disease, etc).

12. Any spinal pathology which can prevent safe administration of epidural/spinal anesthesia

13. Evidence for lymph node involvement of cancer

14. Bladder cancer

15. Urethral stricture/bladder neck contracture

16. Patients with incontinence demonstrated by use of more than 1 pad/day. .

17. Active UTI

18. Prostatitis NIH categories I, II and III.

19. Compromised renal function

20. Interest in future fertility

21. Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostate Disease
• Prostatic Diseases
• Prostatic Neoplasms

Intervention

Device:
• Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.

Locations

Country	Name	City	State
United States	The Smith Institute for Urology	Lake Success	New York
United States	Manhattan Eye, Ear, and Throat Hospital (MEETH)	New York	New York
United States	The Smith Institute for Urology at Lenox Hill	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Northwell Health	Philips Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of safety of the DynaCAD /UroNAV ablation planning and guidance system aided cryo-ablation in the treatment of low-intermediate risk, localized (organ confined) prostate cancer tumors.	Incidence and severity of device/treatment related complications from treatment day visit through 24 month follow up.	24 months
Secondary	Assessment of tumor control achieved by treatment.	Primary effectiveness analyses will be based on the 12-month biopsy results. Post-treatment PSA, non-perfused volume (NPV) by multi-parametric MRI, and EPIC - 26 (The Expanded Prostate Cancer Index Composite) questionnaire results through Month 24 visit will be summarized as secondary measures of effectiveness.	24 months